Suven Life Sciences, a bio-pharmaceutical and contract research and manufacturing company, has granted an exclusive license and right to distribute and market its Malathion Lotion USP 0.5% w/v in USA, Canada and Mexico to Taro Pharmaceuticals North America, Inc., a subsidiary of Taro Pharmaceutical Industries.
Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair. In consideration for the exclusive license and right to distribute and market Malathion Lotion 0.5%w/v USP in North America, Taro will pay Suven a royalty and the arrangement is effective until April 2028 unless otherwise terminated.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
